Mangalam Drugs&Org.
Ticker > Company >

Mangalam Drugs&Org. share price

Mangalam Drugs And Organics Ltd.

  42.81 K   64   6 NSE: MANGALAM BSE: 532637 SECTOR: Pharmaceuticals & Drugs

29.15
-1.59 (-5.17%)
NSE: 01 Oct 4:00 PM

Buy on Angel One

Price Summary

Today's High

₹ 30.89

Today's Low

₹ 28.85

52 Week High

₹ 73.9

52 Week Low

₹ 22.8

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 46.14 Cr.

Enterprise Value

₹ 154.79 Cr.

No. of Shares

1.58 Cr.

P/E

0

P/B

0.48

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  60.51

CASH

₹ 0.67 Cr.

DEBT

₹ 109.33 Cr.

Promoter Holding

35.65 %

EPS (TTM)

₹  -23.78

Sales Growth

-26.9%

ROE

-34.78 %

ROCE

-14.14%

Profit Growth

-732.76 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-26.9%
3 Year-14.57%
5 Year-9.61%

Profit Growth

1 Year-732.76%
3 Year-425.54%
5 Year-209.39%

ROE%

1 Year-34.78%
3 Year-12.06%
5 Year-4.27%

ROCE %

1 Year-14.14%
3 Year-1.5%
5 Year4.1%

Debt/Equity

1.0581

Price to Cash Flow

11.08

Interest Cover Ratio

-1.9607

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2026 35.65 0.00
Mar 2026 35.65 0.00
Dec 2025 35.64 7.09
Sep 2025 50.30 34.58
Jun 2025 50.30 13.23
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 65.9887 days.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 16.371717018698.

 Limitations

  • The company has shown a poor profit growth of -425.539522254948% for the Past 3 years.
  • The company has shown a poor revenue growth of -14.5654712919283% for the Past 3 years.
  • Company has a poor ROE of -12.0555666666667% over the past 3 years.
  • Company has a poor ROCE of -1.502% over the past 3 years
  • Company has low Interest coverage ratio of -1.9607.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 57.21 49.54 58.49 67.29 57.12
Total Expenditure 61.85 52.38 59.96 72.65 56.23
Operating Profit -4.64 -2.83 -1.47 -5.36 0.89
Other Income 0.14 0.03 0.11 0.09 0.11
Interest 4.04 5.03 4.05 3.08 3.68
Depreciation 4.38 4.53 4.37 4.56 3.99
Exceptional Items 0 0 0 0 0
Profit Before Tax -12.93 -12.37 -9.78 -12.92 -6.66
Tax 0.8 -5.12 0 0.15 0.89
Profit After Tax -13.73 -7.25 -9.78 -13.06 -7.55
Adjusted EPS (Rs) -8.67 -4.58 -6.18 -8.25 -4.77

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 451.07 372.25 368.59 317.58 232.13
Total Expenditure 402.01 346.53 351.22 282.43 246.83
Operating Profit 49.05 25.72 17.38 35.15 -14.7
Other Income 0.09 0.44 0.12 1.15 0.76
Interest 11.16 12.96 13.92 14.93 16.21
Depreciation 10.25 10.99 14.63 16.38 17.84
Exceptional Items 0 0 0 0 0
Profit Before Tax 27.73 2.21 -11.06 4.99 -47.99
Tax 8.08 0.94 -2.01 -1.93 -4.17
Net Profit 19.66 1.27 -9.05 6.92 -43.81
Adjusted EPS (Rs.) 12.42 0.8 -5.72 4.37 -27.68

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 15.83 15.83 15.83 15.83 15.83
Total Reserves 134.73 136.13 126.52 132.83 87.49
Borrowings 25.1 18.77 13.35 9.23 7.5
Other N/C liabilities 22.65 23.55 20.49 16.61 7.83
Current liabilities 130.11 163.71 180.95 184.74 189.49
Total Liabilities 328.43 357.98 357.14 359.24 308.14
Assets
Net Block 134.96 142.36 147.31 155.52 148.25
Capital WIP 0.18 0 0 1.38 0
Intangible WIP 5.53 9.49 7.74 1.32 3.88
Investments 0 0 0.03 0.03 0.03
Loans & Advances 2.72 2.86 2.29 1.99 0.28
Other N/C Assets 0 0 0 0 0
Current Assets 185.03 203.26 199.78 199.01 155.69
Total Assets 328.43 357.98 357.14 359.24 308.14
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations 27.73 2.21 -11.06 4.99 -47.99
Adjustment 22.37 24.12 27.81 30.37 32.34
Changes in Assets & Liabilities -15.59 11.72 -4.39 7.49 20.1
Tax Paid -8.81 0.03 -0.19 -0.08 -0.29
Operating Cash Flow 25.71 38.08 12.17 42.76 4.16
Investing Cash Flow -27.33 -22.17 -17.91 -19.47 -11.72
Financing Cash Flow 2.98 -16.82 5.7 -21.71 5.66
Net Cash Flow 1.36 -0.91 -0.04 1.57 -1.9

Corporate Actions

Investors Details

Annual Reports

Title Link
Title Link
Annual Report 2026
Annual Report 2025
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2021
Annual Report 2020
Annual Report 2020
Annual Report 2019
Annual Report 2019
Annual Report 2018
Annual Report 2018
Annual Report 2017
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit INDIA RATINGS & RESEARCH
Credit FITCH
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Mangalam Drugs&Org. Stock Price Analysis and Quick Research Report. Is Mangalam Drugs&Org. an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Mangalam Drugs&Org.. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Mangalam Drugs&Org. has a PE ratio of -1.22584063651197 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Mangalam Drugs&Org. has ROA of -13.1302% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Mangalam Drugs&Org. has a Current ratio of 0.8216.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Mangalam Drugs&Org. has a ROE of -34.7762%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Mangalam Drugs&Org. has a Debt to Equity ratio of 1.0581 which means that the company has low proportion of debt in its capital.

  • Sales growth: Mangalam Drugs&Org. has reported revenue growth of -26.9048% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Mangalam Drugs&Org. for the current financial year is -6.33211090036001%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Mangalam Drugs&Org. is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Mangalam Drugs&Org. is Rs -23.7796. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Mangalam Drugs&Org. in Ticker for free. Also, one can get the intrinsic value of Mangalam Drugs&Org. by using Valuation Calculators, which are available with a Finology ONE subscription. 

Mangalam Drugs&Org. FAQs

Q1. What is Mangalam Drugs&Org. share price today?
Ans: The current share price of Mangalam Drugs&Org. is Rs 29.15.

Q2. What is the market capitalisation of Mangalam Drugs&Org.?
Ans: Mangalam Drugs&Org. has a market capitalisation of Rs 46.13934292 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Mangalam Drugs&Org.?
Ans: The PE ratio of Mangalam Drugs&Org. is -1.22584063651197 and the P/B ratio of Mangalam Drugs&Org. is 0.481776772905469, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Mangalam Drugs&Org. share?
Ans: The 52-week high share price of Mangalam Drugs&Org. is Rs 73.9, and the 52-week low share price of Mangalam Drugs&Org. is Rs 22.8.

Q5. Does Mangalam Drugs&Org. pay dividends?
Ans: Currently, Mangalam Drugs&Org. does not pay dividends. Dividend yield of Mangalam Drugs&Org. is around 0%.

Q6. What are the face value and book value of Mangalam Drugs&Org. shares?
Ans: The face value of Mangalam Drugs&Org. shares is Rs 10, while the book value per share of Mangalam Drugs&Org. is around Rs 60.5052. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Mangalam Drugs&Org.?
Ans: Mangalam Drugs&Org. has a total debt of Rs 109.3259 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Mangalam Drugs&Org.?
Ans: The ROE of Mangalam Drugs&Org. is -34.7762% and ROCE of Mangalam Drugs&Org. is -14.1386%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Mangalam Drugs&Org. a good buy for the long term?
Ans: The Mangalam Drugs&Org. long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Mangalam Drugs&Org. undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Mangalam Drugs&Org. appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Mangalam Drugs&Org.’s financials?
Ans: You can review Mangalam Drugs&Org.’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Mangalam Drugs&Org.
X